GALDERMA GROUP AG (GALDY) - Total Assets
Based on the latest financial reports, GALDERMA GROUP AG (GALDY) holds total assets worth $13.39 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore GALDY operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
GALDERMA GROUP AG - Total Assets Trend (2023–2025)
This chart illustrates how GALDERMA GROUP AG's total assets have evolved over time, based on quarterly financial data. See GALDY book value for net asset value and shareholders' equity analysis.
GALDERMA GROUP AG - Asset Composition Analysis
Current Asset Composition (December 2025)
GALDERMA GROUP AG's total assets of $13.39 Billion consist of 18.2% current assets and 81.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.8% |
| Accounts Receivable | $893.00 Million | 6.7% |
| Inventory | $525.00 Million | 3.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.64 Billion | 34.6% |
| Goodwill | $5.13 Billion | 38.3% |
Asset Composition Trend (2023–2025)
This chart illustrates how GALDERMA GROUP AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GALDY stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GALDERMA GROUP AG's current assets represent 18.2% of total assets in 2025, an increase from 13.0% in 2023.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2025, up from 3.0% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, a decrease from 80.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 38.3% of total assets.
GALDERMA GROUP AG Competitors by Total Assets
Key competitors of GALDERMA GROUP AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
GALDERMA GROUP AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.21 | 1.03 |
| Quick Ratio | 0.93 | 0.94 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $382.00 Million | $315.00 Million | $45.00 Million |
GALDERMA GROUP AG - Advanced Valuation Insights
This section examines the relationship between GALDERMA GROUP AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.99 |
| Latest Market Cap to Assets Ratio | 3.64 |
| Asset Growth Rate (YoY) | 6.2% |
| Total Assets | $13.39 Billion |
| Market Capitalization | $48.78 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values GALDERMA GROUP AG's assets at a significant premium (3.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: GALDERMA GROUP AG's assets grew by 6.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GALDERMA GROUP AG (2023–2025)
The table below shows the annual total assets of GALDERMA GROUP AG from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $13.39 Billion | +6.15% |
| 2024-12-31 | $12.62 Billion | +1.17% |
| 2023-12-31 | $12.47 Billion | -- |
About GALDERMA GROUP AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more